Introduction:
Regorafenib is a third-line option in metastatic CRC, often overshadowed by its limited efficacy and high toxicity. Yet, rare cases of deep and even complete responses hint at untapped potential. This study applies machine learning to transcriptomic and genetic data to identify those exceptional responders—aiming to turn regorafenib into a precision tool rather than a last resort.